

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-122024-0001283

Date: 10.1.25

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Question One:

How many early-stage (non-metastatic or Stages 2-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Chemotherapy
- Radiotherapy
- Chemotherapy AND Radiotherapy

Unable to run a report to provide information by TNM staging

Question Two:

How many patients has your Trust treated in total in the past 3 months for

Stage 2 Non Small Cell Lung Cancer

Stage 3 Non Small Cell Lung Cancer

Unable to run a report to provide information by TNM staging

Question Three:

How many patients who received Pembrolizumab for Non Small Cell Lung Cancer (NSCLC) (any stage) in the last 3 months, received:

Pembrolizumab Monotherapy

Treatment every 3 weeks (200mg, Q3W) 10

Treatment every 6 weeks (400mg, Q6W) 1

Pembrolizumab in combination with chemotherapy

FOI/REF FOI-

Treatment every 3 weeks (200mg, Q3W)	1
Treatment every 6 weeks (400mg, Q6W)	8

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust